FDA adds heart warning to Pfizer anti-smoking pill

June 16, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

The said Thursday a study of 700-heart disease patients taking Chantix showed a small uptick in heart problems among those taking the drug versus those taking placebo. The agency stressed that the drug helped patients quit smoking and that this benefit "should be weighed against its potential risks when deciding to use the drug in smokers with cardiovascular disease."

Chantix is a twice-daily tablet that works by binding to nicotine receptors in the brain, reducing the symptoms of withdrawal.

The FDA will add new warnings to the drug's label about the study's findings. Patients will also receive an updated medication guide with their Chantix prescription that talks about the heart risks.

Drugmaker Pfizer will be required to analyze a large group of studies to further define the heart risk, according to the FDA. The company said in a statement that "the overall rates reported in the study were low."

Approved in May 2006, Chantix has been used by millions of patients in the U.S., though sales have declined since 2008 when the drug was first linked to psychological side effects, including depression and suicidal thoughts. It currently carries a boxed warning, the most serious type, about those risks. GlaxoSmithKline's competing drug, Zyban, carries the same warning.

New York-based . reported sales of $755 million for Chantix last year. Most of the drug's new sales have been driven by patients outside the U.S. Company shares dipped 5 cents to $20.14 in afternoon trading.

shares

Related Stories

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.